MedTrace Logo

Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension

NCT00994617 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2013-06-12

No results posted yet for this study

Summary

To test whether the current custom of initiating treatment for hypertension with a single drug is less effective in the short-term than initial combination therapy, and results in the eventual need for comparatively more antihypertensive drug therapy.

Conditions

  • Hypertension, Resistant to Conventional Therapy
  • Essential Hypertension

Interventions

DRUG

Losartan and hydrochlorothiazide

Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg

DRUG

Hydrochlorothiazide switched over with Losartan at 8 weeks

Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg

Sponsors & Collaborators

Principal Investigators

  • Professor MJ Brown, FMedSci · University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994617 on ClinicalTrials.gov